Marcia Brose, MD, PhD, discusses the safety findings from an analysis of larotrectinib as treatment of patients with metastatic solid tumors.
Marcia Brose, MD, PhD, director of the Center for Rare Cancers and Personalized Therapy, director of the Thyroid Cancer Therapeutics Program, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, and associate professor of Medicine at Penn Medicine, discusses the safety findings from an analysis of larotrectinib (Vitrakvi) as treatment of patients with metastatic solid tumors.
Larotrectinib is extremely well-tolerated, says Brose. According to the poster, which was presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program, there were very few grade 3 toxicities that were attributed to larotrectinib. Overall, the patients appeared to be doing really well on this treatment, says Brose.
The complete response rate with larotrectinib was 10%, and in addition to the patients who are getting deep responses, these data blow almost all of the comparative chemotherapies in each cancer type included in the analysis out of the park, Brose concludes.